Cell stem cell, Journal Year: 2024, Volume and Issue: 31(7), P. 1003 - 1019.e9
Published: May 8, 2024
Language: Английский
Nature, Journal Year: 2023, Volume and Issue: 619(7971), P. 707 - 715
Published: July 26, 2023
Language: Английский
Citations
238
Signal Transduction and Targeted Therapy, Journal Year: 2022, Volume and Issue: 7(1)
Published: June 29, 2022
Abstract Natural killer (NK) cells, a subgroup of innate lymphoid act as the first line defense against cancer. Although some evidence shows that NK cells can develop in secondary tissues, mainly bone marrow (BM) and egress into blood circulation when they mature. They then migrate to settle down peripheral though special subsets home back BM or organs. Owing its success allogeneic adoptive transfer for cancer treatment “off-the-shelf” potential, cell-based immunotherapy is attracting increasing attention various cancers. However, insufficient infiltration adoptively transferred limits clinical utility, especially solid tumors. Expansion engineered chimeric antigen receptor (CAR) ex vivo prior by using cytokines alters profiles chemokine receptors, which affects tumor tissue. Several factors control cell trafficking homing, including cell-intrinsic (e.g., transcriptional factors), cell-extrinsic integrins, selectins, chemokines their corresponding signals induced cytokines, sphingosine-1-phosphate (S1P), etc.), cellular microenvironment. Here, we summarize mechanisms homing at steady state during development, aiming improve immunotherapy.
Language: Английский
Citations
150
Molecular Cancer, Journal Year: 2023, Volume and Issue: 22(1)
Published: Oct. 2, 2023
Abstract Despite centuries since the discovery and study of cancer, cancer is still a lethal intractable health issue worldwide. Cancer-associated fibroblasts (CAFs) have gained much attention as pivotal component tumor microenvironment. The versatility sophisticated mechanisms CAFs in facilitating progression been elucidated extensively, including promoting angiogenesis metastasis, inducing drug resistance, reshaping extracellular matrix, developing an immunosuppressive Owing to their robust tumor-promoting function, are considered promising target for oncotherapy. However, highly heterogeneous group cells. Some subpopulations exert inhibitory role growth, which implies that CAF-targeting approaches must be more precise individualized. This review comprehensively summarize origin, phenotypical, functional heterogeneity CAFs. More importantly, we underscore advances strategies clinical trials CAF various cancers, also progressions immunotherapy.
Language: Английский
Citations
145
International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(8), P. 7493 - 7493
Published: April 19, 2023
The tumor microenvironment (TME) is a critical regulator of growth, progression, and metastasis. Among the innate immune cells recruited to site, macrophages are most abundant cell population present at all stages progression. They undergo M1/M2 polarization in response signals derived from TME. M1 suppress while their M2 counterparts exert pro-tumoral effects by promoting angiogenesis, metastasis, resistance current therapies. Several subsets phenotype have been observed, often denoted as M2a, M2b, M2c, M2d. These induced different stimuli differ phenotypes well functions. In this review, we discuss key features each subset, implications cancers, highlight strategies that being developed harness TAMs for cancer treatment.
Language: Английский
Citations
134
Frontiers in Immunology, Journal Year: 2022, Volume and Issue: 13
Published: Oct. 20, 2022
Tumor microenvironment is the general term for all non-cancer components and their metabolites in tumor tissue. These include extracellular matrix, fibroblasts, immune cells, endothelial cells. In early stages of tumors, has a suppressor function. As progresses, tolerance induced under action various factors, such that continuously transformed into tumor-promoting microenvironment, which promotes escape. Eventually, cells manifest characteristics malignant proliferation, invasion, metastasis, drug resistance. recent years, stress effects metabolic phenotypic changes innate (such as neutrophils, mast cells), adaptive have been revealed to mediate emerging mechanisms tolerance, providing us with large number therapeutic targets relieve tolerance. Gastric cancer one most common digestive tract malignancies worldwide, whose mortality rate remains high. According latest guidelines, first-line chemotherapy advanced gastric traditional platinum fluorouracil therapy, while immunotherapy extremely limited, including only Human epidermal growth factor receptor 2 (HER-2) programmed death ligand 1 (PD-L1) targeted drugs, benefits are limited. Clinical experiments confirmed cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), vascular (VEGFR) other drugs alone or combination limited efficacy patients cancer, far less than lung colon tumors. The failure mainly related induction cancer. Therefore, solving tumors key success immunotherapy. this study, we summarize inducing promoting formation phenotype well research progress targeting overcome treatment
Language: Английский
Citations
89
Signal Transduction and Targeted Therapy, Journal Year: 2024, Volume and Issue: 9(1)
Published: July 1, 2024
The applications of hydrogels have expanded significantly due to their versatile, highly tunable properties and breakthroughs in biomaterial technologies. In this review, we cover the major achievements potential therapeutic applications, focusing primarily on two areas: emerging cell-based therapies promising non-cell modalities. Within context cell therapy, discuss capacity overcome existing translational challenges faced by mainstream therapy paradigms, provide a detailed discussion advantages principal design considerations for boosting efficacy as well list specific examples different disease scenarios. We then explore drug delivery, physical intervention therapies, other areas (e.g., bioadhesives, artificial tissues, biosensors), emphasizing utility beyond mere delivery vehicles. Additionally, complement our latest progress clinical application outline future research directions, particularly terms integration with advanced biomanufacturing This review aims present comprehensive view critical insights into selection both tailored meet requirements diverse diseases situations.
Language: Английский
Citations
83
Molecular Cancer, Journal Year: 2023, Volume and Issue: 22(1)
Published: Nov. 27, 2023
Abstract Immunotherapies have revolutionized the treatment paradigms of various types cancers. However, most these immunomodulatory strategies focus on harnessing adaptive immunity, mainly by inhibiting immunosuppressive signaling with immune checkpoint blockade, or enhancing immunostimulatory bispecific T cell engager and chimeric antigen receptor (CAR)-T cell. Although agents already achieved great success, only a tiny percentage patients could benefit from immunotherapies. Actually, immunotherapy efficacy is determined multiple components in tumor microenvironment beyond immunity. Cells innate arm system, such as macrophages, dendritic cells, myeloid-derived suppressor neutrophils, natural killer unconventional also participate cancer evasion surveillance. Considering that cornerstone antitumor response, utilizing immunity provides potential therapeutic options for control. Up to now, exploiting agonists stimulator interferon genes, CAR-macrophage -natural therapies, metabolic regulators, novel exhibited potent activities preclinical clinical studies. Here, we summarize latest insights into roles cells discuss advances arm-targeted strategies.
Language: Английский
Citations
82
Cancers, Journal Year: 2023, Volume and Issue: 15(7), P. 1987 - 1987
Published: March 26, 2023
Breast cancer is the most common in women and leading cause of death. HER2 overexpression found approximately 20% breast cancers associated with a poor prognosis shorter overall survival. Tratuzumab, monoclonal antibody directed against receptor, standard care treatment. However, third patients do not respond to therapy. Given high rate resistance, other HER2-targeted strategies have been developed, including antibodies such as pertuzumab margetuximab, trastuzumab-based drug conjugates trastuzumab-emtansine (T-DM1) trastuzumab-deruxtecan (T-DXd), tyrosine kinase inhibitors like lapatinib tucatinib, among others. Moreover, T-DXd has proven be use HER2-low subtype, which suggests that therapies could successful this recently defined new subclassification. When progress multiple strategies, there are several available; however, treatment options limited, potential combination drugs, immune checkpoint inhibitors, CAR-T cells, CAR-NK, CAR-M, vaccines an interesting appealing field still development. In review, we will discuss highlights pitfalls different combinations overcome metastatic disease resistance
Language: Английский
Citations
80
Advanced Science, Journal Year: 2022, Volume and Issue: 10(6)
Published: Dec. 25, 2022
Abstract Nano‐immunotherapy has been recognized as a highly promising strategy for cancer treatment in recent decades, which combines nanotechnology and immunotherapy to combat against tumors. Hybrid nanomaterials consisting of at least two constituents with distinct compositions properties, usually organic inorganic, have engineered integrated functions enormous potential boosting immunotherapy. This review provides summary hybrid reported immunotherapy, including nanoscale metal–organic frameworks, metal–phenolic networks, mesoporous organosilica nanoparticles, metallofullerene nanomaterials, polymer–lipid, biomacromolecule‐based nanomaterials. The combination chemotherapy, chemodynamic therapy, radiotherapy, radiodynamic photothermal photodynamic sonodynamic therapy based on is also discussed. Finally, the current challenges prospects designing their application are outlined.
Language: Английский
Citations
72
Molecular Cancer, Journal Year: 2023, Volume and Issue: 22(1)
Published: Feb. 7, 2023
Abstract In recent decades, immune checkpoint blockade and chimeric antigen receptor T cell (CAR-T) therapy are two milestone achievements in clinical immunotherapy. However, both show limited efficacies most solid neoplasms, which necessitates the exploration of new immunotherapeutic modalities. The failure CAR-T several neoplasms is attributed to multiple factors, including low antigenicity tumor cells, infiltration effector diverse mechanisms immunosuppression microenvironment. New adoptive therapies have been attempted for TCR-T, CAR-natural killer cells (CAR-NK), CAR-macrophages (CAR-M). Compared CAR-T, these certain advantages treating neoplasms. this review, we summarized 40-year evolution therapies, then focused on advances CAR-NK, CAR-M discussed their potential applications.
Language: Английский
Citations
67